Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05261399 · ClinicalTrials.gov registry record · Phase 3

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

A Phase 3 study of Carcinoma and Non-Small Cell Lung, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
324
Enrollment target
20
Study locations

NCT05261399 is a Phase 3 study of Carcinoma and Non-Small Cell Lung that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 324 participants, above the 243-participant average among 29 other Carcinoma trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05261399, a Phase 3 study of Carcinoma and Non-Small Cell Lung, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
324 participants
Enrollment target
20
Study locations

Study Summary

Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Conditions Studied

Carcinoma Non-Small Cell Lung

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Osimertinib
  • DRUG Pemetrexed
  • DRUG Savolitinib

Study Locations (20)

Other

  • Research Site - Berazategui
  • Research Site - Buenos Aires
  • Research Site - CABA
  • Research Site - Córdoba
  • Research Site - Florida
  • Research Site - La Rioja
  • Research Site - Rosario

Florida

  • Research Site - Orange City
  • Research Site - Orlando

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

New Jersey

  • Research Site - Florham Park
  • Research Site - New Brunswick

California

  • Research Site - La Jolla

Hawaii

  • Research Site - Honolulu

Illinois

  • Research Site - Evergreen Park

Michigan

  • Research Site - Detroit

Trial Details

FieldValue
Enrollment Target 324 participants
Start Date 2022-08-03
Est. Completion 2026-12-17
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05261399

The ClinicalTrials.gov registry entry for NCT05261399 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 243-participant average among 29 other Carcinoma trials with a reported enrollment target (33% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05261399 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05261399 about?

NCT05261399 is a clinical study titled "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment". Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertini...

What is the current status of trial NCT05261399?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 2022-08-03. Estimated completion is 2026-12-17.

What conditions does trial NCT05261399 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT05261399?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Osimertinib (DRUG), Pemetrexed (DRUG), Savolitinib (DRUG).

Who is sponsoring clinical trial NCT05261399?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05261399 being conducted?

This trial has 20 study locations across California, Florida, Hawaii, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma

All registered trials for this condition

Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.